Actelion was founded in 1997 by a small group of researchers based in Basel, Switzerland.
Led by CEO, Jean-Paul Clozel M.D., the founding members set out to build the company’s legacy on ground-breaking innovation and an unwavering commitment to patients.
The company went public in April 2000 and soon thereafter launched its first product, Tracleer (bosentan), in the US in November 2001. Over time Actelion established an active drug discovery and development organisation, created a sales and marketing organisation that spanned the globe, and acquired four more products. Actelion’s ground-breaking medicines have been a key contributor in the remarkable improvement in prognosis for people with pulmonary arterial hypertension (PAH), with the median survival time more than doubling over the past two decades – now more than seven years with treatment.
Since 2017, Actelion has been a Janssen Pharmaceutical Company of Johnson & Johnson, bringing further resources, capabilities and investment to a renewed focus on work to change the future for people with PAH and other types of cardio-pulmonary diseases. At the time of its acquisition, Actelion employed more than 2,600 people in over 30 affiliates, reaching more than 50 markets.
As part of the Johnson & Johnson Family of Companies Actelion is now leveraging J&J’s established global presence and commercial strength to accelerate patient access to its therapies.
Despite much progress, PAH has no cure and four out of 10 patients die within seven years of diagnosis; but building on its legacy of achievement, Actelion, as part of Johnson & Johnson, is committed to focus on further improving the lives of people affected by pulmonary hypertension, and remains the industry leader in the science and medicine of PAH.
Nominated in 2019